Moreover﻿, SARIFA-positivity provides additional prognostic value within molecular subgroups based on BRAF, RAS, and MMR status, suggesting that it may enhance prognostic stratification of CRC patients. This evidence concerns the gene BRAF and colorectal carcinoma.